PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: A pilot study

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1085-1089

  Dragojevič, Jana ^a   Ostanek, Barbara ^a   Mencej Bedrač, Simona ^a   Komadina, Radko ^b   Preželj, Janez ^c   Marc, Janja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b General and Teaching Hospital Celje   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Bone mineral density; Genetics; High resolution melting; Osteoporosis; RANKL

Indexed keywords

BIOCHEMICAL MARKER; I KAPPA B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; GENOTYPE; HAPLOTYPE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SLOVENIA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CASE-CONTROL STUDIES; GENOTYPE; HAPLOTYPES; HIP FRACTURES; HUMANS; PILOT PROJECTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK; SLOVENIA;

EID: 80051697506     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.981     Document Type: Article

References (35)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994, 843:1-129.
2. Pocock N.A., Eisman J.A., Hopper J.L., Yeates M.G., Sambrook P.N., Eberl S. Genetic determinants of bone mass in adults. A twin study. J Clin Invest 1987, 80:706-710.
3. Guéguen R., Jouanny P., Guillemin F., Kuntz C., Pourel J., Siest G. Segregation analysis and variance components analysis of bone mineral density in healthy families. J Bone Miner Res 1995, 10:2017-2022.
4. Wainwright S.A., Marshall L.M., Ensrud K.E., Cauley J.A., Black D.M., Hillier T.A., et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005, 90:2787-2793.
5. Cranney A., Jamal S.A., Tsang J.F., Josse R.G., Leslie W.D. Low bone mineral density and fracture burden in postmenopausal women. CMAJ 2007, 177:575-580.
6. Justesen J., Stenderup K., Ebbesen E., Mosekilde L., Steiniche T., Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001, 2:165-171.
7. Shen W., Chen J., Punyanitya M., Shapses S., Heshka S., Heymsfield S. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int 2007, 18:641-647.
8. Rzonca S., Suva L., Gaddy D., Montague D., Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
9. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U., Kubota N., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
10. Ali A., Weinstein R., Stewart S., Parfitt A., Manolagas S., Jilka R. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226-1235.
11. Cock T., Back J., Elefteriou F., Karsenty G., Kastner P., Chan S., et al. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004, 5:1007-1012.
12. Rosen E., Sarraf P., Troy A., Bradwin G., Moore K., Milstone D., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4:611-617.
13. Barak Y., Nelson M., Ong E., Jones Y., Ruiz-Lozano P., Chien K., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
14. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A., Saladin R., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272:18779-18789.
15. Vidal-Puig A., Considine R., Jimenez-Liñan M., Werman A., Pories W., Caro J., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422.
16. Mukherjee R., Jow L., Croston G., Paterniti J.J. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272:8071-8076.
17. Kiel D.P., Demissie S., Dupuis J., Lunetta K.L., Murabito J.M., Karasik D. Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet 2007, 8(Suppl. 1):S14.
18. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
19. Masugi J., Tamori Y., Mori H., Koike T., Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000, 268:178-182.
20. Tonjes A., Scholz M., Loeffler M., Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006, 29:2489-2497.
21. Gouda H.N., Sagoo G.S., Harding A.H., Yates J., Sandhu M.S., Higgins J.P. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010, 171:645-655.
22. San-Millan J.L., Escobar-Morreale H.F. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf) 2010, 72:383-392.
23. Xu W., Li Y., Wang X., Chen B., Liu S., Wang Y., et al. PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol Rep 2010, 24:579-585.
24. Muller Y.L., Bogardus C., Beamer B.A., Shuldiner A.R., Baier L.J. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003, 52:1864-1871.
25. Harsløf T., Tofteng C.L., Husted L.B., Nyegaard M., Børglum A., Carstens M., et al. Polymorphisms of the peroxisome proliferator-activated receptor γ (PPARγ) gene are associated with osteoporosis. Osteoporos Int 2010, doi:10.1007/s00198-010-1491-z.
26. Rhee E.J., Oh K.W., Yun E.J., Jung C.H., Park C.Y., Lee W.Y., et al. The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma gene with serum osteoprotegerin levels in healthy Korean women. Exp Mol Med 2007, 39:696-704.
27. Yue H., He J.W., Zhang H., Hu W.W., Hu Y.Q., Li M., et al. No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families. Osteoporos Int 2010, 21:873-882.
28. Rhee E.J., Oh K.W., Lee W.Y., Kim S.Y., Oh E.S., Baek K.H., et al. The effects of C161->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol 2005, 192:1087-1093.
29. Ogawa S., Urano T., Hosoi T., Miyao M., Hoshino S., Fujita M., et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999, 260:122-126.
30. Li G.H., Kung A.W., Huang Q.Y. Common variants in FLNB/CRTAP, not ARHGEF3 at 3p, are associated with osteoporosis in southern Chinese women. Osteoporos Int 2010, 21:1009-1020.
31. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
32. Costa V., Casamassimi A., Esposito K., Villani A., Capone M., Iannella R., et al. Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy. J Biomed Biotechnol 2009, 2009:126917.
33. Ackert-Bicknell C.L., Demissie S., Marín de Evsikova C., Hsu Y.H., DeMambro V.E., Karasik D., et al. PPARG by dietary fat interaction influences bone mass in mice and humans. J Bone Miner Res 2008, 23:1398-1408.
34. Tamaki J., Iki M., Morita A., Ikeda Y., Sato Y., Kajita E., et al. Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int 2010, 21:321-329.
35. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192.